Coronavirus company news summary – Brazil launches clinical trials of Oxford’s Covid-19 vaccine – WHO re-starts paused hydroxychloroquine trial

Allie Nawrat 4 June 2020 (Last Updated June 4th, 2020 09:01)

Brazil’s health regulator Anvisa has approved clinical trials of a Covid-19 vaccine candidate developed by researchers at University of Oxford in the UK and supported by AstraZeneca. The Federal University of Sao Paulo (Unifesp) will help conduct the study, which is set to begin this month and will enrol 2,000 participants.

Novavax has partnered with contract development and manufacturing organisation (CDMO) AGC Biologics for large-scale manufacturing of its Matrix-M adjuvant for its Covid-19 vaccine. AGC Biologics will focus on process development for scaled-up manufacturing of Matrix-M to boost Novavax's capacity to deliver vaccine doses in 2020 and 2021.

The World Health Organization has said that the paused hydroxychloroquine portion of its Solidarity Trial will be resumed. The decision comes after the study's Data Safety and Monitoring Committee reviewed trial data and recommended that it could continue without any modifications.

Revive Therapeutics has submitted an application to Health Canada to conduct a Phase III confirmatory clinical trial of Bucillamine to treat mild to moderate Covid-19. The trial will involve at least 210 patients and will mainly evaluate the drug’s impact on frequency of hospitalisation and mortality.